Intramuscular versus intravenous naloxone for the reversal of methadone overdose in hospitalized patients: a randomized clinical trial

Methadone, a synthetic long-acting opioid, is commonly used in maintenance therapy for opioid addiction. Naloxone is the standard treatment for methadone overdose, capable of reversing opioid effects in both the central and peripheral nervous systems. Continuous naloxone infusion may be required to prevent re-sedation after initial treatment. Given the challenges associated with intravenous administration, alternative delivery methods are under investigation. We aimed to compare the effectiveness of intramuscular (IM) naloxone with intravenous (IV) naloxone in opioid-dependent patients with methadone overdose. A randomized clinical trial was conducted at a tertiary hospital in Tehran, Iran, involving patients with methadone overdose aged 19–59. Patients received either IM or IV naloxone following basic life support and an initial naloxone bolus. In the IV group, approximately two-thirds of the initial effective dose was administered hourly. In the IM group, the dose was adjusted every 4 h based on the calculated hourly requirement: 0.4 mg, 0.8 mg, 1.2 mg, or 1.6 mg, corresponding to calculated needs of < 0.2 mg/h, 0.2–0.4 mg/h, 0.4–0.6 mg/h, or > 0.6 mg/h, respectively. The primary outcome was the occurrence of withdrawal syndrome, assessed using COWS criteria. Naloxone dosing adjustments were guided by venous blood gas analysis and level of consciousness. Treatment response and episodes of apnea were monitored during hospitalization. A total of 160 patients with suspected methadone overdose, randomly assigned to IM or IV naloxone. Normalization of respiratory rate and level of consciousness was comparable between the IM (50.8%) and IV (49.2%) groups ( P > 0.05). COWS scores were significantly higher in the IV group. However, apnea occurred in 20 (25%) cases in the IM group and 18 (22.5%) cases in the IV group during hospitalization, each requiring a single rescue dose of naloxone. IM naloxone resulted in a significantly lower median [IQR] pulse rate (76 [70, 80] vs. 98 [88, 110] in the IV group) at four hours post-intervention. Oxygen saturation and pCO 2 levels post-naloxone were similar between the two groups. IM naloxone was associated with less severe opioid withdrawal, reflected by lower COWS scores and may represent a reasonable alternative to intravenous naloxone in selected clinical settings. However, these findings should be interpreted with caution because of the single-center design, potential variability in naloxone dosing, concomitant substance use, and the lack of confirmatory toxicological testing. Trial registration: IRCT20120629010133N6. Registered 01 January 2023.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-18
DOI
https://doi.org/10.1038/s41598-026-64972-0
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intramuscular versus intravenous naloxone for the reversal of methadone overdose in hospitalized patients: a randomized clinical trial

Ali‐Asghar Kolahi, Niloofar Deravi, Nicholas Allan Buckley, Ali Jangjou et al.
Scientific Reports
Opioid Use Disorder Treatment
article

Intramuscular versus intravenous naloxone for the reversal of methadone overdose in hospitalized patients: a randomized clinical trial

Ali‐Asghar Kolahi, Niloofar Deravi, Nicholas Allan Buckley, Ali Jangjou, Mahbobeh Taheri, Amir Hossein Hassani, Hossein Hassanian‐Moghaddam, Rebecca McDonald
article en

Abstract

Methadone, a synthetic long-acting opioid, is commonly used in maintenance therapy for opioid addiction. Naloxone is the standard treatment for methadone overdose, capable of reversing opioid effects in both the central and peripheral nervous systems. Continuous naloxone infusion may be required to prevent re-sedation after initial treatment. Given the challenges associated with intravenous administration, alternative delivery methods are under investigation. We aimed to compare the effectiveness of intramuscular (IM) naloxone with intravenous (IV) naloxone in opioid-dependent patients with methadone overdose. A randomized clinical trial was conducted at a tertiary hospital in Tehran, Iran, involving patients with methadone overdose aged 19–59. Patients received either IM or IV naloxone following basic life support and an initial naloxone bolus. In the IV group, approximately two-thirds of the initial effective dose was administered hourly. In the IM group, the dose was adjusted every 4 h based on the calculated hourly requirement: 0.4 mg, 0.8 mg, 1.2 mg, or 1.6 mg, corresponding to calculated needs of < 0.2 mg/h, 0.2–0.4 mg/h, 0.4–0.6 mg/h, or > 0.6 mg/h, respectively. The primary outcome was the occurrence of withdrawal syndrome, assessed using COWS criteria. Naloxone dosing adjustments were guided by venous blood gas analysis and level of consciousness. Treatment response and episodes of apnea were monitored during hospitalization. A total of 160 patients with suspected methadone overdose, randomly assigned to IM or IV naloxone. Normalization of respiratory rate and level of consciousness was comparable between the IM (50.8%) and IV (49.2%) groups ( P > 0.05). COWS scores were significantly higher in the IV group. However, apnea occurred in 20 (25%) cases in the IM group and 18 (22.5%) cases in the IV group during hospitalization, each requiring a single rescue dose of naloxone. IM naloxone resulted in a significantly lower median [IQR] pulse rate (76 [70, 80] vs. 98 [88, 110] in the IV group) at four hours post-intervention. Oxygen saturation and pCO 2 levels post-naloxone were similar between the two groups. IM naloxone was associated with less severe opioid withdrawal, reflected by lower COWS scores and may represent a reasonable alternative to intravenous naloxone in selected clinical settings. However, these findings should be interpreted with caution because of the single-center design, potential variability in naloxone dosing, concomitant substance use, and the lack of confirmatory toxicological testing. Trial registration: IRCT20120629010133N6. Registered 01 January 2023.

Scientific ReportsVol. 16(1)
The University of Sydney (AU), Shiraz University (IR), Shiraz University of Medical Sciences (IR), Curtin University (AU), Next Step Drug and Alcohol Services (AU), Royal Perth Bentley Group (AU), National Drug Research Institute (AU), Shahid Beheshti University (IR), Shahid Beheshti University of Medical Sciences (IR)
Shahid Beheshti University of Medical Sciences
Good health and well-being
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon